Skip to main content
Advertisement
Advertisement

SNTI

SNTI logo

Senti Biosciences Holdings, Inc. Common Stock

0.32
USD
Sponsored
+0.01
+1.81%
Sep 22, 15:33 UTC -4
Closed
exchange

After-Market

0.34

+0.02
+6.15%

SNTI Earnings Reports

Positive Surprise Ratio

SNTI beat 8 of 11 last estimates.

73%

Next Report

Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
-$0.30
Implied change from Q2 26 (Revenue/ EPS)
-100.00%
/
-26.83%
Implied change from Q3 25 (Revenue/ EPS)
--
/
-56.52%

Senti Biosciences Holdings, Inc. Common Stock earnings per share and revenue

On Aug 14, 2026, SNTI reported earnings of -0.41 USD per share (EPS) for Q2 26, missing the estimate of -0.27 USD, resulting in a -51.68% surprise. Revenue reached 17.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a -4.23% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.30 USD, with revenue projected to reach -- USD, implying an decrease of -26.83% EPS, and decrease of -100.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
logo
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
logo
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
logo
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
logo
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
logo
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
logo
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
logo
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
logo
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
logo
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
FAQ
For Q2 2026, Senti Biosciences Holdings, Inc. Common Stock reported EPS of -$0.41, missing estimates by -51.68%, and revenue of $17.00K, 0% as expectations.
The stock price moved down -4.23%, changed from $0.45 before the earnings release to $0.43 the day after.
The next earning report is scheduled for Nov 09, 2026.
Based on -- analysts, Senti Biosciences Holdings, Inc. Common Stock is expected to report EPS of -$0.30 and revenue of -- for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement